Acerux250 mg/vial

Acerux 250 mg/vial cream is a herpes simplex virus (HSV) nucleoside analogue DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.

Topical Antiviral preparations

Acerux 250 mg/vial is an antiviral drug active against herpes simplex virus. Acerux 250 mg/vial is a synthetic purine nucleoside analogue with cell culture and in vivo inhibitory activity against HSV types 1 (HSV-1) and 2 (HSV-2). The inhibitory activity of Acerux 250 mg/vial is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV. This viral enzyme converts Acerux 250 mg/vial into Acerux 250 mg/vial monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In cell culture, Acerux 250 mg/vial triphosphate stops replication of herpes viral DNA. This inhibition is accomplished in 3 ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase.

Acerux 250 mg/vial cream should be applied five times per day for four days. Therapy should be initiated as early as possible following the onset of signs or symptoms of herpes labialis i.e., during the prodrome or when lesions appear. For adolescents 12 years of age and older, the dosage is the same as in adults.

Clinical experience has identified no interactions resulting from topical or systemic administration of other drugs concomitantly with Acerux 250 mg/vial cream. Due to minimal systemic absorption of Acerux 250 mg/vial cream, systemic drug interactions are unlikely.

Acerux 250 mg/vial cream is contraindicated in patients with known hypersensitivity to Acerux 250 mg/vial, valAcerux 250 mg/vial, or any component of the formulation.

The most common adverse reactions at the site of topical application were dry lips, desquamation, dryness of skin, cracked lips, burning skin, pruritus, flakiness of skin, and stinging on skin; each adverse reaction occurred in less than 1% of patients receiving Acerux 250 mg/vial cream and placebo. Three patients on Acerux 250 mg/vial cream and one patient on placebo discontinued treatment due to an adverse event.

Pregnancy Category B. There are no adequate and well-controlled studies of Acerux 250 mg/vial cream in pregnant women. Acerux 250 mg/vial cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether topically applied Acerux 250 mg/vial is excreted in breast milk. Systemic exposure following topical administration is minimal.

Acerux 250 mg/vial cream should only be applied on the affected external aspects of the lips and face in patients with herpes labialis. Because no data are available, application to human mucous membranes is not recommended. Acerux 250 mg/vial cream is intended for cutaneous use only and should not be used in the eye or inside the mouth or nose. Cream has a potential for irritation and contact. The effect of Acerux 250 mg/vial cream has not been established in immunocompromised patients.

Store Acerux 250 mg/vial cream at room temperature between 20°C to 25°C

Pediatric Use: An open-label, uncontrolled trial with Acerux 250 mg/vial cream 5% was conducted in 113 patients aged 12 to 17 years with recurrent herpes labialis. In this trial, therapy was applied using the same dosing regimen as in adults and subjects were followed for adverse events. The safety profile was similar to that observed in adults. Safety and effectiveness in pediatric patients less than 12 years of age have not been established.Geriatric Use: Clinical studies of Acerux 250 mg/vial cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Systemic absorption of Acerux 250 mg/vial after topical administration is minimal.